% | $
Quotes you view appear here for quick access.

Facebook, Inc. (FB) Message Board

fternoss 2 posts  |  Last Activity: May 8, 2016 12:56 AM Member since: Apr 11, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "In May 2012, Elizabeth Mittendorf, M.D., Ph.D., an assistant professor in the Department of Surgical Oncology, and her colleagues published the 24-month landmark analysis of their phase I and II trials of E75.

    Excerpt From OncoLog, January 2013, Vol. 58, No. 1

    "The group’s findings opened the door to the phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study, currently the only phase III trial of a breast cancer vaccine. Dr. Mittendorf is the overall principal investigator of the multinational study.

    This randomized, double-blind, placebo-controlled trial will enroll approximately 700 breast cancer patients who were rendered disease free following standard treatment. Patients must be positive for HLA-A2 or HLA-A3 and have had cancers that were scored as HER2 1+ or 2+ by immunohistochemistry. The vaccine will be given once a month for 6 months and then given as a booster inoculation every 6 months thereafter through 3 years. Because GM-CSF causes inflammation at the injection site, it will be given to patients in each study group, serving as the immunoadjuvant for the vaccine group and as an active placebo for the control group. The primary endpoint of the study is 3-year disease-free survival.

    Positive results from this trial, researchers hope, would eventually lead to indications for the E75 vaccine in the routine care of breast cancer patients. “We are all cautiously optimistic—and excited—as we wait for the results. If they do show that E75 has significant benefit, it could be an amazing opportunity for our cancer patients,” Dr. Litton said"

  • Reply to


    by arndace2 Dec 17, 2015 5:13 PM
    fternoss fternoss Dec 17, 2015 9:14 PM Flag

    If what you say is true, the balance sheet does not matter. I can tag along and ride the manipulation until I decide that I am happy with my profit or the chart reverses course. AMD has gone up 60%. If I waited from the balance sheet to improve before I got in, I would have missed the 60% move

    So, what's your point?

128.27+0.18(+0.14%)Sep 30 4:00 PMEDT